Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer.

The tumour suppressor gene TP53 and its downstream effector p21 are thought to play major roles in the development of breast cancer. We investigated three common sequence variants in TP53 and p21 for possible associations with the risk of breast cancer and with various phenotypic features of this disease. A total of 351 cases were available for study. Germline DNA obtained from female subjects of similar age but without cancer was used to estimate the TP53 and p21 genotype frequencies in a control population. A single nucleotide polymorphism in intron 2 of p21 was associated with slightly increased breast cancer risk (RR = 1.4, P = 0.011) and with well/moderately differentiated tumour histology (P = 0.029). The 16 bp insertion polymorphism in intron 3 of TP53 was associated with poor histological grade (OR = 2.3, P = 0.013) independently of other pathological features. The codon 31 polymorphism in p21 was strongly linked to negative progesterone receptor status (OR = 3.4, P = 0.0001), suggesting this variant may have functional significance for the progesterone signalling pathway in breast cancer. These results add to the growing body of evidence that genetic variants can influence not only the risk of breast cancer but also the disease phenotype.

[1]  N. Park,et al.  Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. , 2001, Cancer letters.

[2]  A. Scorilas,et al.  Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer , 2001, British Journal of Cancer.

[3]  L. Hutchins,et al.  Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. , 2000, Cancer research.

[4]  Stephen M. Mount,et al.  Genomic sequence, splicing, and gene annotation. , 2000, American journal of human genetics.

[5]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[6]  B. Wasylyk,et al.  Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  B. Weber,et al.  Low penetrance genes associated with increased risk for breast cancer. , 2000, European journal of cancer.

[8]  B. Iacopetta,et al.  Routine analysis of p53 mutation in clinical breast tumor specimens using fluorescence-based polymerase chain reaction and single strand conformation polymorphism. , 2000, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[9]  B. Weber,et al.  Assessing the risk of breast cancer. , 2000, The New England journal of medicine.

[10]  B. Ponder,et al.  A Systematic Review Of Genetic Polymorphisms and Breast Cancer Risk 1 , 2000 .

[11]  N. Roodi,et al.  Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.

[12]  T. Rebbeck,et al.  p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. , 1998, Anticancer research.

[13]  K. Horwitz,et al.  Progesterone Regulates Transcription of the p21 WAF1 Cyclindependent Kinase Inhibitor Gene through Sp1 and CBP/p300* , 1998, The Journal of Biological Chemistry.

[14]  I. Campbell,et al.  TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. , 1998, British Journal of Cancer.

[15]  B. Iacopetta,et al.  Detection of p53 gene mutation by rapid PCR‐SSCP and its association with poor survival in breast cancer , 1997, International journal of cancer.

[16]  K. Horwitz,et al.  Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.

[17]  S. Sukumar,et al.  Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  M. Becich,et al.  Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin‐dependent kinase inhibitor gene , 1997, Cancer.

[19]  N. Day,et al.  Family history and the risk of breast cancer: A systematic review and meta‐analysis , 1997, International journal of cancer.

[20]  S. Avigad,et al.  A novel germ line p53 mutation in intron 6 in diverse childhood malignancies , 1997, Oncogene.

[21]  I. Bleiweiss,et al.  p53 haplotype determination in breast cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  W. Foulkes,et al.  Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours. , 1996, European journal of cancer.

[23]  S. Al-Sedairy,et al.  Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. , 1996, British Journal of Cancer.

[24]  X. Montano,et al.  Analysis of intron 4 of the p53 gene in human cutaneous melanoma. , 1996, Gene.

[25]  R. Birgander,et al.  Association between the p21 codon 31 A1 (arg) allele and lung cancer. , 1996, Human heredity.

[26]  G. Hallmans,et al.  p53 polymorphisms and haplotypes in breast cancer. , 1996, Carcinogenesis.

[27]  D. Eccles,et al.  p53 polymorphism in ovarian and breast cancer , 1996, The Lancet.

[28]  V. Rotter,et al.  A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. , 1995, DNA and cell biology.

[29]  J. Lancaster,et al.  p53 polymorphism in ovarian and bladder cancer , 1995, The Lancet.

[30]  P. D. Lee,et al.  Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. , 1995, Human Molecular Genetics.

[31]  R. Kreienberg,et al.  p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer , 1995, The Lancet.

[32]  L. Poston,et al.  Insulin resistance and membrane abnormalities , 1995, The Lancet.

[33]  B. Vogelstein,et al.  Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.

[34]  D. Givol,et al.  A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. , 1994, Oncogene.

[35]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[36]  V. Lazar,et al.  Simple sequence repeat polymorphism within the p53 gene. , 1993, Oncogene.

[37]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[38]  S. Pacini,et al.  Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. , 1998, Oncology research.

[39]  S. Groshen,et al.  WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. , 1997, The American journal of pathology.

[40]  A. Marchetti,et al.  Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. , 1995, International journal of oncology.